ZAI LAB LIMITED Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
ZAI LAB LIMITED (ZLAB) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 11.41 million shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2026-08-06
- ZAI LAB LIMITED share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-06-30 was 4.05M shares, a 95.66% increase year-over-year.
- ZAI LAB LIMITED share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-03-31 was 7.36M shares, a 45.31% increase year-over-year.
- ZAI LAB LIMITED share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-12-31 was 373.00K shares, a 86.50% increase year-over-year.
- ZAI LAB LIMITED share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-09-30 was 209.00K shares, a 2486.63% increase year-over-year.
- ZAI LAB LIMITED share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2025 was 7.72M shares, a 63.16% decline from fiscal 2024.
- ZAI LAB LIMITED share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2024 was 20.95M shares, a 13.09% decline from fiscal 2023.
- ZAI LAB LIMITED share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2023 was 24.10M shares, a 6.79% increase from fiscal 2022.
- ZAI LAB LIMITED share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2022 was 22.57M shares, a 2975.52% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month |
|---|---|---|---|---|
| 2026-06-30 | 4.05M shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | 11.41M shares 10-Q · filed 2026-08-06 | 11.78M shares derived: sum of 3 quarters · filed 2026-08-06 | 11.99M shares derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | 7.36M shares 10-Q · filed 2026-05-07 | 7.73M shares derived: sum of 2 quarters · filed 2026-05-07 | 7.94M shares derived: sum of 3 quarters · filed 2026-05-07 | 10.01M shares derived: sum of 4 quarters · filed 2026-05-07 |
| 2025-12-31 | 373.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | 582.00K shares derived: sum of 2 quarters · filed 2026-02-26 | 2.65M shares derived: sum of 3 quarters · filed 2026-02-26 | 7.72M shares 10-K · filed 2026-02-26 |
| 2025-09-30 | 209.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | 2.28M shares derived: sum of 2 quarters · filed 2025-11-06 | 7.34M shares 10-Q · filed 2025-11-06 | 7.54M shares derived: sum of 4 quarters · filed 2025-11-06 |
| 2025-06-30 | 2.07M shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | 7.13M shares 10-Q · filed 2025-08-07 | 7.33M shares derived: sum of 3 quarters · filed 2025-08-07 | 7.34M shares derived: sum of 4 quarters · filed 2025-08-07 |
| 2025-03-31 | 5.06M shares 10-Q · filed 2025-05-08 | 5.26M shares derived: sum of 2 quarters · filed 2025-05-08 | 5.27M shares derived: sum of 3 quarters · filed 2025-05-08 | |
| 2024-12-31 | 200.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | 208.08K shares derived: sum of 2 quarters · filed 2025-02-27 | 20.95M shares 10-K · filed 2025-02-27 | |
| 2024-09-30 | 8.08K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | 20.75M shares 10-Q · filed 2024-11-12 | ||
| 2024-06-30 | 20.74M shares 10-Q · filed 2024-08-06 | |||
| 2023-12-31 | 24.10M shares 10-K · filed 2024-02-27 | |||
| 2022-12-31 | 22.57M shares 10-K · filed 2023-03-01 | |||
| 2021-12-31 | 733.89K shares 10-K · filed 2022-03-01 | |||
| 2020-12-31 | 1.22M shares 10-K · filed 2021-03-01 | |||
| 2020-06-30 | 960.88K shares 6-K · filed 2020-09-11 | |||
| 2019-12-31 | 1.07M shares 10-K · filed 2021-03-01 | |||
| 2019-06-30 | 649.19K shares 6-K · filed 2020-09-11 | |||
| 2018-12-31 | 2.76M shares 10-K · filed 2021-03-01 | |||
| 2017-12-31 | 264.48K shares 20-F · filed 2020-04-29 | |||
| 2016-12-31 | 2.92M shares 20-F · filed 2019-03-29 | |||
| 2015-12-31 | 4.31M shares 20-F · filed 2018-04-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |